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Background: This study analyzed the relation between the tumor 
size and the lymph node metastasis in adenocarcinoma of the lung 
with a size of 30 mm or smaller.
Methods: Four hundred thirteen patients who had undergone cura-
tive resection for lung adenocarcinoma were enrolled. If the tumor 
presented ground-glass opacities on the preoperative high-resolution 
computed tomography, both the total size including ground-glass 
opacities and the solid size alone were measured. To calculate the 
rates of lymph node metastasis by the tumor size, the tumors were 
divided into six groups by their sizes: 5 mm or less, 6 to 10 mm, 11 to 
15 mm, 16 to 20 mm, 21 to 25 mm, and 26 to 30 mm.
Results: The average numbers of dissected lymph nodes and dis-
sected lymph node stations were 17 and 5, respectively. Seventy-five 
patients (18%) were postoperatively discovered to have positive nodes. 
The rates of node metastasis in each total size group were 0/1 (0%), 
0/29 (0%), 5/77 (7%), 17/121 (14%), 27/101 (27%), and 26/84 (31%), 
respectively. The rates of node metastasis in each solid size group were 
0/37 (0%), 1/53 (2%), 9/88 (10%), 17/104 (16%), 23/78 (30%), and 
25/53 (47%), respectively. The area under the curve of receiver operat-
ing characteristic curves for the total size was measured as 0.701, and 
that for the solid size was measured as 0.777. By multivariate analysis, 
solid size, maximum standardized uptake value, and lymphovascular 
invasion were independent significant predictive factors.
Conclusions: Solid size, maximum standardized uptake value, and 
lymphovascular invasion were independent predictors for lymph node 
metastasis of lung adenocarcinoma. The size of the solid component 
explained the relation between the tumor size and the lymph node 
metastasis more accurately than that explained by the total tumor size 
on high-resolution computed tomography.
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Tumor size and lymph node status are recognized to be the most powerful predictors of prognosis and are funda-
mental elements in the tumor-node-metastasis (TNM) stag-
ing system. Generally, larger tumors have been known to be 
more closely associated with lymph node involvement in solid 
tumors including lung cancer.1,2 However, a positive correla-
tion between the tumor size and lymph node metastasis does 
not necessarily exist in all types of lung cancer. Some stud-
ies have reported that small squamous cell carcinoma tumors 
are not generally related to lymph node metastasis, but small 
adenocarcinoma tumors tend to present with lymph node 
metastasis.3,4
The number of cases of early detection of lung cancer 
has recently been increasing with the help of computed tomog-
raphy (CT) screening and regular health examinations for lung 
cancer.5,6 Lung cancer detected by means of CT screening is 
more likely to be small in size and peripherally located, and 
also to present with mainly an adenocarcinoma histology, 
especially from the in situ component.5,7 Accordingly, the 
pathologic characteristics or prognosis of this type of lung 
cancer have been extensively studied, and surgeons have made 
attempts to minimize the volume of lung that is to be resected 
on the basis of size.
In making decisions on limited resection, consider-
ing that the size of the tumor cannot be the sole factor to be 
evaluated—given the risk of unknown lymph node status 
even with small tumors, research on the association between 
lymph node metastasis and the size of adenocarcinoma with 
a ground-glass opacities (GGOs) component would be benefi-
cial for predicting prognosis and making reliable decisions on 
the basis of limited resections.
Therefore, this study analyzed the relation between the 
tumor size and lymph node metastasis in adenocarcinoma of 
the lung with a size of 30 mm or smaller on preoperative CT.
PATIENTS AND METHODS
Patient Population
This study is a retrospective review of a prospective 
lung cancer database. Patients enrolled in this study had 
undergone curative resection at Seoul National University 
Bundang Hospital from January 2004 to December 2012 
and were diagnosed pathologically with lung adenocarci-
noma. Patients who underwent neoadjuvant therapy and 
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patients who presented with tumors larger than 30 mm were 
excluded from this study. This study was approved by the 
Institutional Review Board of Seoul National University 
Bundang Hospital. Informed consent was waived because it 
was a retrospective review.
Preoperative Evaluations
A contrast-enhanced chest CT or high-resolution CT 
was performed in all the patients preoperatively. For partly 
solid GGOs, the images were photographed with a window 
level of −600 Hounsfield Units (H) and a window width of 
2000 H as the lung window. GGO was defined as a hazy 
increase in lung attenuation without obscuring the underly-
ing bronchial or vascular structures, and solid attenuation 
was defined as an increase in lung attenuation obscuring the 
underlying structures.8 If the tumor presented GGOs, both the 
total size including GGOs and the solid size were measured. 
Otherwise, only the total size of the tumor was measured. All 
measurements were performed retrospectively by a radiolo-
gist and surgeons who did not know the pathologic results. 
The largest transverse  cross-sectional diameter of the area 
of GGO in the lung window and the remaining solid area in 
mediastinal window image were measured. For manual diam-
eter measurements, we used the electronic calipers function 
of our picture archiving and communication system on the 
axial image in which the GGO had the greatest dimension. 
Readers were advised to zoom in on the nodule for more 
accurate analysis. Spiculations were included in the determi-
nation of the largest transverse  cross-sectional diameter of 
the speculated nodule (Fig. 1). To calculate the rates of lymph 
node metastasis by the tumor size, the tumors were divided 
into six groups by their sizes: 5 mm or less, 6 to 10 mm, 
11 to 15 mm, 16 to 20 mm, 21 to 25 mm, and 26 to 30 mm. 
Adenocarcinoma with GGOs was grouped in the same man-
ner but separately by the total size and the solid size.
As a standard staging procedure, positron emission 
tomography/CT was performed with an integrated posi-
tron emission tomography/CT scanner (Discovery VCT; GE 
Healthcare, Milwaukee, WI) and the maximum standardized 
uptake value (SUVmax) of the main tumor was assessed.
The tumor locations were assessed with bronchoscopy, 
and if the bronchoscopic findings showed a visible lesion, it 
was defined as central. If no visible lesion was found, it was 
defined as peripheral.
Surgical Treatment
Lobectomy combined with mediastinal lymph node dis-
section by thoracotomy or video-assisted thoracic surgery was 
performed as the standard surgical procedure. However, seg-
mentectomy was selectively performed in patients with a partly 
solid GGO that was 10 mm or smaller. All patients underwent 
mediastinal lymph node dissection. This study also excluded 
patients who presented less than six lymph nodes or who did 
not undergo dissection of the hilar, subcarinal, and paratracheal 
(right side), or aortopulmonary window lymph nodes (left side).
Pathology
Diagnostic evaluation of lymph node metastasis was 
done using hematoxylin and eosin staining. The status of 
lymph node involvement was recorded as N1 or N2 depending 
on their locations, and its count was also recorded. The histo-
pathological classification of the specimens was done on the 
basis of the International Association for the Study of Lung 
Cancer/American Thoracic Society/European Respiratory 
Society classification of lung adenocarcinoma.9 The tumors 
were classified as adenocarcinoma in situ, minimally invasive 
adenocarcinoma, and invasive adenocarcinoma. Visceral pleu-
ral invasion was assessed in all the cases, using the guidelines 
of the 7th edition of the TNM classification for lung cancer. 
Lymphovascular invasion was also examined.
Statistical Analysis
The Student’s t test and analysis of variance were used 
to compare the distribution of continuous data, and Fisher’s 
exact or χ2 tests were used to compare the frequencies of cat-
egorical measures among different groups. Receiver operat-
ing characteristic curves and the area under the curve (AUC) 
of the total size, solid size, and SUVmax were generated to 
determine the cutoff value and whether the total size or solid 
size was more highly predictive of lymph node metastasis. 
The statistical analysis was performed using IBM SPSS 20.0 
software (IBM Co., Chicago, IL). All p values less than 0.05 
were considered to be statistically significant.
RESULTS
Patient Characteristics
This study enrolled 413 patients who were diagnosed 
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December 2012 (Table 1). Among them, 198 patients (48%) 
were male and 215 patients (52%) were female. The mean age 
was 62.0 years (range, 26–84). Two hundred forty-seven of 
those patients (60%) were never smokers, 106 patients (26%) 
were exsmokers, and 60 patients (14%) were current smokers. 
Surgical resection that was more extensive than segmentec-
tomy was performed in 379 patients (92%) and segmentec-
tomy was performed in 34 patients (8%).
One hundred ninety-one patients (46%) presented partly 
solid GGO nodules on preoperative CT, and 222 patients (54%) 
presented 100% solid tumors. In terms of in situ lesions on 
pathologic examination, 155 patients (38%) presented tumors 
combined with an in situ component, whereas 258 patients 
(62%) presented 100% invasive tumors.
Forty-two patients who had partly solid GGO lesions on 
preoperative CT revealed no in situ lesion on pathologic find-
ings; in contrast, six patients with only a solid lesion on CT 
showed an in situ lesion on pathologic findings after surgery.
Tumor Size
Of the 413 patients enrolled in the study, the median 
total size of the tumor was 20.0 (6.0–30.0) mm, whereas the 
median size of the solid component was only 17.0 (0.0–30.0) 
mm. After the tumors were divided into six groups by their 
total sizes (≤5, 6–10, 11–15, 16–20, 21–25, and 26–30 mm), 
the numbers of patients in each group were calculated to be 
0 (0%), 30 (7%), 77 (19%), 121 (29%), 101 (25%), and 84 
(20%), respectively. The tumors were also classified accord-
ing to the sizes of only the solid component in the same man-
ner, and the numbers of patients in each group were 37 (9%), 
53 (13%), 88 (21%), 104 (25%), 78 (19%), and 53 (13%), 
respectively. The total tumor sizes of those 37 patients were 
measured, and there were 11 patients in the 6 to 10 mm group, 
13 in the 11 to 15 mm group, eight in the 16 to 20 mm, two in 
the 21 to 25 mm, and three in the 26 to 30 mm groups.
Frequency of Lymph Node Metastasis
The average numbers of dissected lymph nodes and dis-
sected lymph node stations were 17.6 (range, 6–57) and 4.6, 
respectively. Seventy-five patients (18%) were postoperatively 
discovered to have positive nodes. Forty-one of those patients 
(10%) were diagnosed with pathologically positive N1 nodes, 
and 34 patients (8%) were diagnosed with pathologically 
positive N2 nodes. The average number of involved lymph 
nodes was 4.4 (1–12) in patients who experienced lymph node 
metastasis. The mean total number of dissected lymph nodes 
was 16.8 and 8.8 in the lobectomy and segmentectomy group, 
and there were no positive nodes in the segmentectomy group.
Correlation between Total Tumor 
Size and LN Metastasis
The proportions of node metastasis in each total size 
group in order from the smallest diameter to the largest 
(≤5, 6–10, 11–15, 16–20, 21–25, and 26–30 mm) were 0/1 
(0%), 0/30 (0%), 5/77 (7%), 17/121 (14%), 27/101 (27%), 
and 26/84 (31%), respectively, which showed a statistically 
significant increase in the rate of the lymph node metastasis 
with increasing tumor size (p < 0.001) (Table 2).
Correlation between Solid Component 
Size and LN Metastasis
The rates of node metastasis in each invasive size group 
were 0/37 (0%), 1/53 (2%), 9/88 (10%), 17/104 (16%), 23/78 
(30%), and 25/53 (47%), respectively, which also showed a 
statistically significant increase in the rates of lymph node 
metastasis with increasing solid component size (p < 0.001) 
(Table 2).
Comparison of Predictability of LN 
Metastasis by Total Size and Solid Size
Predictability of lymph node metastasis was evaluated 
by using a receiver operating characteristic curve. The AUC 
for the total size of the tumor was measured as 0.701 (95% 
CI = 0.641–0.761), and that for the solid size of the tumor 
was measured as 0.777 (95% CI = 0.724–0.829; Fig. 2). This 
result showed that the use of the solid size would produce 
more accurate predictions of lymph node metastasis. For the 
ever-smokers and nonsmokers, the AUC for the total tumor 
size and the solid size were 0.680/0.740 and 0.713/0.800, 
respectively.
Correlation between Tumor 
Size and Node Location
In terms of the metastatic nodes by location, the fre-
quency of N1 involvement was the same in the 26 to 30 mm 
group as in the 21 to 25 mm group on the basis of the solid size 
of the tumors (Table 3). However, there was a positive correla-
tion presented between the frequency of N2 involvement and 
the solid size of the tumor. There was no metastatic N2 found 




  Male 198 (47.9)
  Female 215 (52.1)
Age, yr, mean (range) 62.0 (26–84)
Smoking, n (%)
  Never 247 (59.8)
  Exsmoker 106 (25.7)
  Current smoker 60 (14.5)
Consistency on CT, n (%)
  Partly solid 191 (46.2)
  Pure solid 222 (53.8)
Consistency on pathology, n (%)
  Including in situ component 155 (37.5)
  Invasive only 258 (62.5)
Extent of surgery, n (%)
  Lobectomy 378 (91.8)
  Segmentectomy 34 (8.2)
CT, computed tomography.
821Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 6, June 2014 Frequency of Lymph Node Metastasis
Stations of Metastatic LNs According 
to Tumor Locating Lobes
Multistation N1 lymph node metastasis was common 
in the tumors located in the right upper lobe or left lower 
lobe (Table 4). In N2 lymph node metastasis, the upper 
zone was a common site of LN metastasis from the right 
upper lobe tumors, the aortopulmonary zone from the LUL 
tumors, and the subcarinal zone from the tumors located in 
both lower lobes.
Correlation of Other Factors with LN Metastasis
The mean SUVmax was 3.3, and mean SUVmax of 
the node-negative patients and node-positive patients were 
2.4 and 4.9, respectively, which were significantly different 
(p < 0.001) (Table 5). However, there was no significant differ-
ence between N1- and N2-positive patients (4.9 in N1 versus 
4.5 in N2, p = 0.418).
At a cutoff value of 2.5, patients with a high SUVmax 
(66 of 183, 36%) had a greater incidence of LN metastasis 
compared with that in those with a low value (9 of 230, 4%).
The eight of 17 (47%) of the centrally located tumors 
and 67 of 396 (17%) of the peripheral tumors showed LN 
metastasis, respectively, and this was statistically significant. 
LN metastasis was evaluated according to tumor differentia-
tion, and the frequencies of LN metastasis were 10% (6 of 
63) in well, 18% (15 of 82) in moderate, and 35% (7 of 20) 
in poor differentiation. LN metastasis was found in 38 of 302 
(13%) of the tumors with no visceral pleural invasion and 37 
of 111 (37%) of the tumors with visceral pleural invasion. By 
multivariate analysis, solid size (cutoff value = 2.0), SUVmax 
(cutoff value = 2.5), and lymphovascular invasion were inde-
pendent significant predictive factors for LN metastasis.
DISCUSSION
This study focused on analyzing the tumor size and its 
association with lymph node metastasis in lung adenocarci-
noma with a size of 30 mm or smaller. Generally, the frequency 
of lymph node metastasis has been known to increase as the 
tumor size increases,10–12 and the data from this study were 
in accordance with this, showing a sequential increase in the 
rate of node metastasis from the smallest tumor group (2%) to 
the largest tumor group (40%). There are several well-known 
factors for lymph node metastasis in non–small-cell lung can-
cer, such as the degree of differentiation, visceral pleural inva-
sion, amount of GGO, lymphovascular invasion, and tumor 
size,7,10,13–16 and rather than acting individually, these factors 
interact together and influence lymph node metastasis. In our 
study, solid size, SUVmax, and lymphovascular invasion were 
statistically independent risk factors for lymph node metasta-
sis by multivariate analysis. Okada et al. identified 2.5 as an 
optimal cutoff value for the SUVmax to predict high-grade 
malignancy and concluded that SUVmax is a significant pre-
operative predictor for surgical outcomes in clinical stage IA 
adenocarcinoma.
However, until now, few studies have evaluated LN 
metastasis by precise tumor size in adenocarcinoma less than 
30 mm. Especially, given that the detection of adenocarci-
noma with GGO in asymptomatic patients has increased, it is 
important to evaluate the maximum size of a tumor that can 
be expected not to be associated with lymph node metastasis.
Lobectomy with systemic mediastinal lymph node 
dissection has been believed to be the appropriate surgical 
procedure for pathologic stage IA lung cancer because a pro-
spective randomized trial was performed by the Lung Cancer 
Study Group.17 However, it may not be appropriate to simply 
apply the old theory to the treatment of lung cancer recently 
detected by CT screening programs. Therefore, many studies 







Size (mm) ≤5 5<, ≤10 10<, ≤15 15<, ≤20 20<, ≤25 25<, ≤30 p
Total size, n (%) 0 (0.0) 30 (7.0) 77 (18.6) 121 (29.3) 101 (24.5) 84 (20.3)
  Positive LN, n (%) 0 (0.0) 0 (0.0) 5 (6.5) 17 (14.0) 27 (26.7) 26 (30.9) <0.001
Solid size, n (%) 37 (9.0) 53 (12.8) 88 (21.3) 104 (25.2) 78 (18.9) 53 (12.8)
  Positive LN, n (%) 0 (0.0) 1 (1.9) 9 (10.2) 17 (16.3) 23 (29.5) 25 (47.2) <0.001
LN, lymph node. 
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tumors are being carried out.5,18 The major concern at this 
point is that a critical range for the tumor diameter with 
which there is no lymph node metastasis found should be 
identified. If we could identify tumors within this size range 
preoperatively, limited resection without lymph node dissec-
tion could be performed safely for these cases. Oda et al.11 
reported a 22% incidence of node metastasis among 524 
patients with non–small-cell lung cancer and noted that none 
of the patients with adenocarcinoma with a size of 10 mm or 
smaller presented lymph node metastasis, whereas there was 
a 20.8% incidence of lymph node metastasis in adenocarci-
noma tumors with a size of 11 to 20 mm. Tsutani et al.16 sug-
gested that pathologic  node-negative criteria such as a solid 
tumor size less than 8 mm on high-resolution CT may be 
helpful for avoiding systemic lymphadenectomy for clinical 
stage IA lung adenocarcinoma. We determined that there was 
no lymph node metastasis found in tumors with a solid com-
ponent size of 5 mm or smaller, and only one patient expe-
rienced lymph node metastasis among 53 patients who had 
a tumor with a solid size of 10 mm or smaller. This patient, 
in fact, presented a 7-mm-sized invasive component, which 
means that all the patients with a solid tumor size smaller 
than 7 mm had no lymph node metastasis. On the basis of 
the findings from the present study, lymph node dissection 
seems to be unnecessary in tumors with an invasive size of 
5 mm or smaller.
Another important aim of this study was analyz-
ing whether the total size or the solid size of the tumor is a 
more reliable factor for predicting lymph node metastasis. 
In patients with adenocarcinoma combined with an in situ 
component, although both the total tumor size and the solid 
component size were found to be important factors for lymph 
node involvement, the size of the solid component has gener-
ally been considered a more reliable factor. Furthermore, the 
solid component shown on preoperative CT was closely cor-
related with the invasive component on pathologic examina-
tion. Yanagawa et al. showed that the total tumor size was not 
correlated with disease-free survival (DFS), whereas the inva-
sive tumor size was significantly correlated with DFS. They 
reported that DFS in patients with an invasive tumor smaller 
than 5 mm was 100% and noted that the invasive tumor size 
is a very useful predictor of recurrence.19 The present study 
also found that the size of the solid component is a more use-
ful factor than the total tumor size for predicting lymph node 
metastasis. Therefore, as a factor for predicting lymph node 
metastasis, the evaluation of the solid size, rather than the total 
tumor size, is suggested in patients with adenocarcinoma with 
an in situ component.
A high SUVmax of a tumor is known to be correlated 
with advanced stage, poor survival, or recurrence in adeno-
carcinoma.20 Miyata et al. identified an optimal cutoff value 
of 2.5 for the SUVmax to predict high-grade malignancy and 
reported 21.4% LN metastasis in patients with an SUVmax of 
greater than 2.5. They concluded that a high SUVmax signifi-
cantly correlated with a high carcinoembryonic antigen level, 
lymphatic invasion, vascular invasion, pleural invasion, and 
lymph node metastasis.21 In present study, the mean SUVmax 
of node-positive patients was significantly higher than that of 
the node-negative patients, and 36% of the patients with an 
SUVmax of 2.5 or greater had LN metastasis.
TAbLE 3.  Correlation between Solid Size of Tumor and Positive Lymph Node Location
Solid Size (mm) ≤5 5<, ≤10 10<, ≤15 15<, ≤20 20<, ≤25 25<, ≤30
N0, n (%) 37 (10.9) 52 (15.4) 79 (23.4) 87 (25.7) 55 (16.3) 28 (8.3)
N1, n (%) 0 (0.0) 1 (2.4) 2 (4.9) 10 (24.4) 14 (34.1) 14 (34.1)
N2, n (%) 0 (0.0) 0 (0.0) 7 (20.6) 7 (20.6) 9 (26.5) 11 (32.4)
TAbLE 4.  Station of Metastatic Lymph Nodes According to Tumor Locating Lobes
RUL (n = 138) RML (n = 44) RLL (n = 78) LUL (n = 94) LLL (n = 68)
N1, n (%)
  Hilar 1 (5.3) 0 (0.0) 1 (8.3) 1 (4.8) 0 (0.0)
  Interlobar 5 (26.3) 2 (28.6) 6 (50.0) 2 (9.5) 0 (0.0)
  Lobar 7 (36.8) 4 (57.1) 3 (25.0) 16 (76.2) 1 (11.1)
  Hilar + interlobar 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (11.1)
  Hilar + lobar 2 (10.5) 0 (0.0) 1 (8.3) 1 (4.8) 1 (11.1)
  Interlobar + lobar 2 (10.5) 1 (14.3) 1 (8.3) 0 (0.0) 4 (44.4)
  Hilar + interlobar + lobar 2 (10.5) 0 (0.0) 0 (0.0) 1 (4.8) 2 (22.2)
N2, n (%)
  Upper 6 (85.7) 1 (16.7) 0 (0.0) 1 (9.1) 0 (0.0)
  Subcarinal 1 (14.3) 1 (16.7) 3 (100.0) 0 (0.0) 3 (42.9)
  AP window 0 (0.0) 0 (0.0) 0 (0.0) 8 (72.7) 2 (28.6)
  Two stations 0 (0.0) 4 (66.7) 0 (0.0) 0 (0.0) 2 (28.6)
  Three stations 0 (0.0) 0 (0.0) 0 (0.0) 2 (18.2) 0 (0.0)
RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe, LUL, left upper lobe; LLL, left lower lobe; AP, aortopulmonary.
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CONCLUSIONS
Solid size, SUVmax, and lymphovascular invasion were 
independent predictors for lymph node metastasis of lung ade-
nocarcinoma. There was no lymph node metastasis detected 
in patients with adenocarcinoma combined with an in situ 
component in which the solid component size was 5 mm or 
smaller. The size of the solid component explained the rela-
tion between the tumor size and the lymph node metastasis 
more accurately than that explained by the total tumor size. 
On the basis of the results from this study, a reliable guideline 
could be established to avoid unnecessary limited resection or 
lymph node dissection.
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TAbLE 5.  Univariate and Multivariate Analyses of Positive Node
Node Negative Node Positive Univariate Analysis
Multivariate Analysis
HR (95% CI)
Total size, n (%) <0.001 0.888
1.190 (0.106–13.339)
  ≤2.0 206 (90.4) 22 (9.6)
  >2.0 132 (71.4) 53 (28.6)
Solid size, n (%) <0.001 0.048
9.627 (0.923–100.390)
  ≤2.0 255 (90.4) 27 (9.6)
  >2.0 83 (63.4) 48 (36.6)
SUVmax, n (%) <0.001 0.001
16.885 (3.166–90.054)
  ≤2.5 221 (96.1) 9 (3.9)
  >2.5 117 (63.9) 66 (36.1)
Differentiation, n (%) 0.045 0.221
0.31 (0.112–1.660)
  Well 57 (90.5) 6 (9.5)
  Moderate/poor 80 (78.4) 22 (21.6)
VPI, n (%) <0.001 0.181
2.183 (0.696–6.845)
  No 264 (87.4) 38 (12.6)
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